Globus Medical upgraded by Piper Sandler with a new price target
$GMED
Medical/Dental Instruments
Health Care
Piper Sandler upgraded Globus Medical from Neutral to Overweight and set a new price target of $80.00 from $60.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/10/2025 | $97.00 | Underperform → Neutral | BofA Securities |
| 12/2/2024 | $83.00 → $100.00 | Equal-Weight → Overweight | Morgan Stanley |
| 8/7/2024 | $60.00 → $78.00 | Equal Weight → Overweight | Wells Fargo |
| 5/20/2024 | $60.00 → $80.00 | Neutral → Overweight | Piper Sandler |
| 3/18/2024 | $60.00 | Neutral → Buy | BTIG Research |
| 10/20/2023 | $75.00 | Buy | ROTH MKM |
| 9/19/2023 | $61.00 | Hold → Buy | Stifel |
| 3/30/2023 | $67.00 | Hold → Buy | Canaccord Genuity |
AUDUBON, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2024. Worldwide net sales were $625.7 million, an increase of 63.1%GAAP net income for the quarter was $51.8 millionGAAP diluted earnings per share ("EPS") was $0.38 and non-GAAP diluted EPS was $0.83Non-GAAP adjusted EBITDA was $193.7 million, or 31.0% of net sales "Our third quarter results reflect the enduring strength of our business. We've continued to deliver on our business objectives to drive sales growth, launch new products, and execute our integration plans, all while delivering
AUDUBON, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the third quarter ended September 30, 2024 after the market close on Tuesday, November 5, 2024. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-w
AUDUBON, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2024. Worldwide net sales were $629.7 million, an increase of 115.9% or 117.3% on a constant currency basisGAAP net income for the quarter was $31.8 millionGAAP diluted earnings per share ("EPS") was $0.23 and non-GAAP diluted EPS was $0.75Non-GAAP adjusted EBITDA was $190.4 million, or 30.2% of net sales "I'm pleased with the quarterly results, demonstrating our team's strong performance as we continue to execute our long-term growth strategy, deliver on NuVasive integration plans, laun
8-K - GLOBUS MEDICAL INC (0001237831) (Filer)
10-Q - GLOBUS MEDICAL INC (0001237831) (Filer)
8-K - GLOBUS MEDICAL INC (0001237831) (Filer)
BofA Securities upgraded Globus Medical from Underperform to Neutral and set a new price target of $97.00
Morgan Stanley upgraded Globus Medical from Equal-Weight to Overweight and set a new price target of $100.00 from $83.00 previously
Wells Fargo upgraded Globus Medical from Equal Weight to Overweight and set a new price target of $78.00 from $60.00 previously
4 - GLOBUS MEDICAL INC (0001237831) (Issuer)
4 - GLOBUS MEDICAL INC (0001237831) (Issuer)
4 - GLOBUS MEDICAL INC (0001237831) (Issuer)
AUDUBON, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ending December 31, 2024. The company anticipates fourth quarter 2024 sales of approximately $657.0 million, an increase of 6.6 percent over the fourth quarter 2023 on an as-reported basis. Full year 2024 sales are expected to be approximately $2.52 billion, an increase of 60.6 percent over the prior year on an as-reported basis. "2024 was an exceptional year of execution and achievement for Globus Medical. With the NuVasive merger, we believe we created the strongest sales fo
AUDUBON, Pa., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced the commercial launch of the ExcelsiusHub™ navigation system. ExcelsiusHub™ joins the expansive ecosystem of Excelsius™ technologies and is designed to elevate the standard for freehand navigation. Freehand navigation provides surgeons with real-time visualization of instrument placement, to reduce the reliance on X-ray imaging during spine surgery. This also facilitates accurate placement of screws and interbody spacer implants and may reduce OR radiation when compared to conventional fluoroscopy. ExcelsiusHub™ offers advantages over other n
AUDUBON, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2024. Worldwide net sales were $625.7 million, an increase of 63.1%GAAP net income for the quarter was $51.8 millionGAAP diluted earnings per share ("EPS") was $0.38 and non-GAAP diluted EPS was $0.83Non-GAAP adjusted EBITDA was $193.7 million, or 31.0% of net sales "Our third quarter results reflect the enduring strength of our business. We've continued to deliver on our business objectives to drive sales growth, launch new products, and execute our integration plans, all while delivering
SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)
SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)
SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)
MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders. "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics. "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced the appointment of veteran medical technology industry executive David M. Demski to its board of directors, effective January 1, 2021. Mr. Demski currently serves as president and CEO of Globus Medical, Inc. (Nasdaq: GMED), a publicly traded medical technology company that manufactures and markets musculoskeletal implants and related surgical products, with sales in 2019 of over $750 million and a curren
EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics, with a focus on oncology and infectious diseases including COVID-19, today announced the recent appointments of Richard Baron to Immunome’s Board of Directors and as Audit Committee Chair, and Sandra Stoneman, Esq. as Chief Legal Officer and Corporate Secretary. The company also today announced that its President and Chief Executive Officer, Purnanand Sarma, Ph.D. is the recipient of TiE Boston’s 2020 Lifetime Achievement Award. The award recognizes individuals who have made invaluab